Tue, Jul 22, 2014, 7:59 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Trius Therapeutics, Inc. (TSRX) Message Board

  • kovted kovted Jul 30, 2013 7:28 PM Flag

    BUYOUT OF TRIUS - LAW FIRM SEEKS HIGHER PRICE FOR SHAREHOLDERS

     

    NEW YORK-
    Tripp Levy PLLC, a leading national securities and shareholder rights law firmis investigating the Board of Directors of Trius Therapeutics, Inc. (“Trius” or the “Company”) (TSRX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc. (CBST).

    Under the terms of the transaction, Trius shareholders will receive $13.50 in cash for each share of Trius stock they own. Trius shareholders will also be eligible to receive one Contingent Value Right of up to $2.00 per share should certain commercial milestones be met. The investigation concerns whether the Trius Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether Cubist Pharmaceuticals, Inc. is underpaying for Trius, thus unlawfully harming Trius shareholders. In particular, at least one analyst set a price target for Trius stock at $20.00 per share.

    If you own common stock in Trius and wish to obtain additional information, please contact us at 1-877-772-3975 or email at contact @ tripplevy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.